Research & Development Overview

Fixx Pharmaceuticals research and development resources are devoted to identifying next-generation therapies for Hemophilia and other inherited bleeding disorders.  

What We Hope To Achieve

In Q4 of 2021, Fixx hopes to begin its first clinical trial to investigate the effectiveness of gene editing by using custom-matched zinc finger nucleases.  (ZFNs)


By using ZFNs specific for the factor 8 and Factor 9 genes in conjunction with its DNA sequence, Fixx hopes to restore normal gene function in hemophilia patients.


Disclaimer: Nothing on Fixx Pharmaceuticals should be construed as medical advice or replace medical advice, medical visits, or recommendations from a health care professional. Patients should always consult with a doctor or other health care professional for medical advice. 

  • Facebook
  • Instagram
  • Twitter
  • YouTube

© 2020 - 2021 Fixx Pharmaceuticals, Inc